{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:50:10Z","timestamp":1784605810572,"version":"3.55.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A disease risk index (DRI) that was developed for adults with hematologic malignancy who were undergoing hematopoietic cell transplantation is also being used to stratify children and adolescents by disease risk. Therefore, to develop and validate a DRI that can be used to stratify those with AML and ALL by their disease risk, we analyzed 2569 patients aged &amp;lt;18 years with acute myeloid (AML; n = 1224) or lymphoblastic (ALL; n = 1345) leukemia who underwent hematopoietic cell transplantation. Training and validation subsets for each disease were generated randomly with 1:1 assignment to the subsets, and separate prognostic models were derived for each disease. For AML, 4 risk groups were identified based on age, cytogenetic risk, and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2, 3, 5), high (7, 8), and very high (&amp;gt;8) risk groups was 78%, 53%, 40%, and 25%, respectively (P &amp;lt; .0001). For ALL, 3 risk groups were identified based on age and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2-4), and high (\u22655) risk groups was 68%, 51%, and 33%, respectively (P &amp;lt; .0001). We confirmed that the risk groups could be applied to overall survival, with 5-year survival ranging from 80% to 33% and 73% to 42% for AML and ALL, respectively (P &amp;lt; .0001). This validated pediatric DRI, which includes age and residual disease status, can be used to facilitate prognostication and stratification of children with AML and ALL for allogeneic transplantation.<\/jats:p>","DOI":"10.1182\/blood.2020009342","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T01:24:33Z","timestamp":1605749073000},"page":"983-993","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation"],"prefix":"10.1182","volume":"137","author":[{"given":"Muna","family":"Qayed","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Emory University School of Medicine, Atlanta, GA;"},{"name":"Children\u2019s Healthcare of Atlanta, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-8037","authenticated-orcid":false,"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"},{"name":"Division of Biostatics, Institute for Heath and Equity, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Stem Cell Transplant, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam H.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-3952","authenticated-orcid":false,"given":"Christopher","family":"Dvorak","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation, Benioff Children\u2019s Hospital, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mellgren","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-4400","authenticated-orcid":false,"given":"Brian D.","family":"Friend","sequence":"additional","affiliation":[{"name":"Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[{"name":"Division of Cancer and Blood Disorders, Department of Pediatrics, University Of Colorado, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Leung","sequence":"additional","affiliation":[{"name":"Pediatric Academic Clinical Program, Duke-National University of Singapore (NUS) Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-0651","authenticated-orcid":false,"given":"Jacek","family":"Toporski","sequence":"additional","affiliation":[{"name":"Section of Pediatric Hematology, Oncology, Immunology and Nephrology, Department of Pediatrics, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Levine","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-5890","authenticated-orcid":false,"given":"Joseph","family":"Chewning","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Wayne","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Children\u2019s Hospital of Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-9980","authenticated-orcid":false,"given":"Brandon","family":"Triplett","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation, St Jude Children's Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Yanik","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, C.S. Mott Children\u2019s Hospital, The University of Michigan, Ann Arbor, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"},{"name":"Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2022041419423978600_B1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2022041419423978600_B2","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2022041419423978600_B3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2022041419423978600_B4","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"25","key":"2022041419423978600_B5","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1182\/blood-2012-02-392506","article-title":"How I treat pediatric acute myeloid leukemia","volume":"119","author":"Rubnitz","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2022041419423978600_B6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"2022041419423978600_B7","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.bbmt.2018.12.384","article-title":"Disease Risk Index Predicts Relapse in Children Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)","volume":"25","author":"Qayed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2022041419423978600_B8","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/sj.leu.2403924","article-title":"Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials","volume":"19","author":"Gibson","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"2022041419423978600_B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","article-title":"Pediatric acute lymphoblastic leukemia version 2.2020 NCCN Clinical Practice Guides in OIncology","volume":"18","author":"Brown","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2022041419423978600_B10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression model and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series BN"},{"issue":"6","key":"2022041419423978600_B11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/bimj.200610301","article-title":"Consistent estimation of the expected Brier score in general survival models with right-censored event times","volume":"48","author":"Gerds","year":"2006","journal-title":"Biom J"},{"issue":"2","key":"2022041419423978600_B12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1541-0420.2010.01459.x","article-title":"A robust alternative to the schemper-henderson estimator of prediction error","volume":"67","author":"Schmid","year":"2011","journal-title":"Biometrics"},{"key":"2022041419423978600_B13","article-title":"SurvAUC: Estimators of prediction accuracy for time-to-event data. R package version 1.0-5","author":"Poptapov","year":"2012"},{"issue":"16","key":"2022041419423978600_B14","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022041419423978600_B15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial [published correction appears in Lancet Oncol. 2010;11(6):516]","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2022041419423978600_B16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I treat infant leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022041419423978600_B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/leu.2016.165","article-title":"Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin","volume":"31","author":"Cruickshank","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2022041419423978600_B18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/MOP.0000000000000866","article-title":"The future of cellular immunotherapy for childhood leukemia","volume":"32","author":"Bonifant","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"2022041419423978600_B19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fped.2019.00401","article-title":"Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention [published correction appears in Front Pediatr. 2019;7:466]","volume":"7","author":"Mercher","year":"2019","journal-title":"Front Pediatr"},{"issue":"4","key":"2022041419423978600_B20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.16203","article-title":"Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup","volume":"188","author":"Hara","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2022041419423978600_B21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/gcc.20335","article-title":"High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9","volume":"45","author":"von Bergh","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"2022041419423978600_B22","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"de Rooij","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2022041419423978600_B23","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"2022041419423978600_B24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fped.2019.00463","article-title":"Targeted Therapies for Pediatric AML: Gaps and Perspective","volume":"7","author":"Lonetti","year":"2019","journal-title":"Front Pediatr"},{"issue":"22","key":"2022041419423978600_B25","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2019000357","article-title":"Opportunities for immunotherapy in childhood acute myeloid leukemia","volume":"3","author":"Lamble","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2022041419423978600_B26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions [published correction appears in Nat Med. 2018;24(4):526]","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2022041419423978600_B27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2010.153","article-title":"Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol","volume":"24","author":"van der Velden","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"2022041419423978600_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.65.65","article-title":"Impact of residual disease on survival in pediatric patients receiving allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission [abstract]","volume":"122","author":"Horan","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2022041419423978600_B29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2022041419423978600_B30","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bbmt.2018.06.010","article-title":"Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: Validation of difference from normal flow cytometry with chimerism studies and Wilms Tumor 1 gene expression","volume":"24","author":"Jacobsohn","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2022041419423978600_B31","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022041419423978600_B32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2022041419423978600_B33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022041419423978600_B34","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"2022041419423978600_B35","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2022041419423978600_B36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","article-title":"Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients","volume":"5","author":"Tichelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"16","key":"2022041419423978600_B37","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2022041419423978600_B38","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2022041419423978600_B39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","article-title":"Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy","volume":"123","author":"Eapen","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2022041419423978600_B40","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2014-05-576041","article-title":"Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation","volume":"124","author":"Pidala","year":"2014","journal-title":"Blood"},{"key":"2022041419423978600_B41","article-title":"Comparison of total body irradiation versus non- total body irradiation containing regimens for de novo acute myeloid leukemia in children published online before print 20 June 2018]","author":"Dandoy","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/137\/7\/983\/1888235\/bloodbld2020009342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/137\/7\/983\/1888235\/bloodbld2020009342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T16:51:12Z","timestamp":1723913472000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/7\/983\/474200\/A-validated-pediatric-disease-risk-index-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009342","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}